No Data
No Data
No Data
No Data
No Data
Analytical Instrument Management Acquires PSI Laboratories
LITTLETON, Colo., April 18, 2024 /PRNewswire/ -- Analytical Instrument Management (AIM) proudly announces its acquisition of PSI Laboratories, a well-established full-service analytical laboratory ba
PR NewswireApr 18 08:34 ET
Express News | AIM ImmunoTech Announces Charles Lapp, Md, as a Consulting Medical Officer for Its Me/Cfs and Long Covid Programs
Moomoo 24/7Apr 15 08:55 ET
Press Release: AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM ImmunoTech Announces Release of the Next CEO Corner Segment OCALA, Fla., April 11, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company"), today announced the
Dow JonesApr 11 11:00 ET
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
OCALA, Fla., April 11, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company"), today announced the next CEO Corner segment has been published on the Company's website. For the CEO
AIM ImmunoTechApr 11 00:00 ET
Express News | AIM ImmunoTech Announces Top-Line, Protocol-Planned Interim Report Data From Study Of Ampligen Combined With Pembrolizumab For Recurrent Ovarian Cancer
Moomoo 24/7Apr 10 08:22 ET
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data From the Study of Ampligen Combined With Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
OCALA, Fla., April 10, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM") today announced top-line interim data indicating that combining Ampligen (rintatolimod) with Keytruda (pembrolizumab)
AIM ImmunoTechApr 10 00:00 ET
No Data
No Data